{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:22:52Z","timestamp":1792174972746,"version":"4.4.0"},"reference-count":61,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":339,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                    <jats:p\/>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>RET is a key oncogene in neuroendocrine cancer. Pathogenic germline variants lead to multiple different phenotypes, including multiple endocrine neoplasia type 2, medullary thyroid cancer (MTC), Hirschsprung disease and kidney malformations. Pathogenic somatic variants are also associated with MTC, and RET rearrangements are observed in papillary thyroid cancer, non-small cell lung cancer and pan-cancer syndromes. Testing for both germline and somatic variants is now feasible in everyday clinical practice, and their identification has important clinical consequences, both for affected individuals and their families. This mini-review will discuss current germline and somatic testing strategies in the UK and worldwide, as well as reporting and test outcomes (including variants of uncertain significance or incidental findings). It will explore actions following identification of a pathogenic germline variant, including predictive, reproductive and childhood testing, and somatic testing of RET variants in solid tumours informing personalised cancer treatment. Finally, it will discuss the challenge of delivering rapid and equitable access to genomic testing to ensure that all individuals can benefit promptly and appropriately to improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/erc-24-0230","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T12:55:03Z","timestamp":1742993703000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":4,"title":["Genomic testing for\n                    <i>RET<\/i>\n                    in the clinic: UK and global perspective"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-4843","authenticated-orcid":true,"given":"Louise","family":"Izatt","sequence":"first","affiliation":[{"name":"Consultant in Clinical Genetics, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, Guy\u2019s Hospital 1 , ,","place":["London, United Kingdom"]},{"name":"Honorary Senior Lecturer, Department of Medical and Molecular Genetics, Guy\u2019s Campus, King\u2019s College London 2 , ,","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2026070905463179900_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"2026070905463179900_bib2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1210\/me.2003-0173","article-title":"Biological effects of the dual phenotypic janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and hirschsprung\u2019s disease","volume":"18","author":"Arighi","year":"2004","journal-title":"Mol Endocrinol"},{"key":"2026070905463179900_bib3","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/hmg\/4.8.1381","article-title":"Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease","volume":"4","author":"Atti\u00e9","year":"1995","journal-title":"Hum Mol Genet"},{"key":"2026070905463179900_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann Oncol"},{"key":"2026070905463179900_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s40142-019-00169-4","article-title":"Clinical analysis of whole genome sequencing in cancer patients","volume":"7","author":"Berner","year":"2019","journal-title":"Curr Genet Med Rep"},{"key":"2026070905463179900_bib6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182a6f43a","article-title":"Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective","volume":"259","author":"Brauckhoff","year":"2014","journal-title":"Ann Surg"},{"key":"2026070905463179900_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7861\/clinmedicine.17-6-545","article-title":"The rise of the genome and personalised medicine","volume":"17","author":"Brittain","year":"2017","journal-title":"Clin Med"},{"key":"2026070905463179900_bib8","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0117","article-title":"RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis","volume":"30","author":"Bulanova Pekova","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026070905463179900_bib9","first-page":"264","article-title":"Interpreting and integrating genomic tests results in clinical cancer care: overview and practical guidance","volume":"74","author":"Casolino","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026070905463179900_bib10","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1530\/ERC-17-0209","article-title":"A comprehensive review on MEN2B","volume":"25","author":"Castinetti","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026070905463179900_bib11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"2026070905463179900_bib12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00383-014-3538-2","article-title":"The association between Hirschsprung\u2019s disease and multiple endocrine neoplasia type 2a: a systematic review","volume":"30","author":"Coyle","year":"2014","journal-title":"Pediatr Surg Int"},{"key":"2026070905463179900_bib13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00467-013-2606-5","article-title":"To bud or not to bud: the RET perspective in CAKUT","volume":"29","author":"Davis","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"2026070905463179900_bib14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41431-022-01091-0","article-title":"Recommendations for reporting results of diagnostic genomic testing","volume":"30","author":"Deans","year":"2022","journal-title":"Eur J Hum Genet"},{"key":"2026070905463179900_bib15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"Den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"2026070905463179900_bib16","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.3390\/cancers15164146","article-title":"RET-altered cancers \u2013 a tumor-agnostic review of biology, diagnosis and targeted therapy activity","volume":"15","author":"Desilets","year":"2023","journal-title":"Cancers"},{"key":"2026070905463179900_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/367378a0","article-title":"Mutations of the RET proto-oncogene in Hirschsprung's disease","volume":"367","author":"Edery","year":"1994","journal-title":"Nature"},{"key":"2026070905463179900_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-020-01420-w","article-title":"Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN)","volume":"15","author":"Eggermann","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2026070905463179900_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000346174","article-title":"2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer","volume":"1","author":"Elisei","year":"2012","journal-title":"Eur Thyroid J"},{"key":"2026070905463179900_bib20","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/genes10090698","article-title":"Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations","volume":"10","author":"Elisei","year":"2019","journal-title":"Genes"},{"key":"2026070905463179900_bib21","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis","volume":"276","author":"Eng","year":"1996","journal-title":"JAMA"},{"key":"2026070905463179900_bib22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070905463179900_bib23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/cen.14395","article-title":"Diagnostic RET genetic testing in 1,058 index patients: a UK centre perspective","volume":"95","author":"Fussey","year":"2021","journal-title":"Clin Endocrinol"},{"key":"2026070905463179900_bib24","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070905463179900_bib25","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of clinical genome resource (ClinGen), cancer genomics consortium (CGC), and variant interpretation for cancer consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med"},{"key":"2026070905463179900_bib26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/cen.14596","article-title":"A practical guide to genetic testing in endocrinology","volume":"97","author":"Izatt","year":"2022","journal-title":"Clin Endocrinol"},{"key":"2026070905463179900_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.638093","article-title":"The emerging genetic landscape of Hirschsprung disease and its potential clinical applications","volume":"9","author":"Karim","year":"2021","journal-title":"Front Pediatr"},{"key":"2026070905463179900_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","article-title":"Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations","volume":"34","author":"Kuzbari","year":"2023","journal-title":"Ann Oncol"},{"key":"2026070905463179900_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/EC-20-0163","article-title":"Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study","volume":"9","author":"Larsen","year":"2020","journal-title":"Endocr Connections"},{"key":"2026070905463179900_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and College of American pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"2026070905463179900_bib31","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.gim.2022.05.002","article-title":"Reclassification of clinically-detected sequence variants: framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK)","volume":"24","author":"Loong","year":"2022","journal-title":"Genet Med"},{"key":"2026070905463179900_bib32","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1210\/jc.2017-02529","article-title":"p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer","volume":"103","author":"Loveday","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905463179900_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0000000000001009","article-title":"Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results","volume":"36","author":"Machens","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"2026070905463179900_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051024","article-title":"Non-invasive prenatal diagnosis of multiple endocrine neoplasia type 2A using COLD-PCR combined with HRM genotyping analysis from maternal serum","volume":"7","author":"Macher","year":"2012","journal-title":"PLoS One"},{"key":"2026070905463179900_bib35","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/humu.24486","article-title":"Multiple endocrine neoplasia type 2 (MEN2) and RET specific modifications of the ACMG\/AMP variant classification guidelines and impact on the MEN2 RET database","volume":"43","author":"Margraf","year":"2022","journal-title":"Hum Mutat"},{"key":"2026070905463179900_bib36","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/jc.2016-3640","article-title":"Risk profile of the RET A883F germline mutation: an international collaborative study","volume":"102","author":"Mathiesen","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905463179900_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100866","article-title":"ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Miller","year":"2023","journal-title":"Genet Med"},{"key":"2026070905463179900_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.6061\/clinics\/2012(Sup01)12","article-title":"The Hirschsprung's-multiple endocrine neoplasia connection","volume":"67","author":"Moore","year":"2012","journal-title":"Clinics"},{"key":"2026070905463179900_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2026070905463179900_bib40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cen.14818","article-title":"Approach to the patient with a variant of uncertain significance on genetic testing","volume":"97","author":"Newey","year":"2022","journal-title":"Clin Endocrinol"},{"key":"2026070905463179900_bib41","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070905463179900_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/oncolo\/oyac264","article-title":"RET fusion-positive non-small cell lung cancer: the evolving treatment landscape","volume":"28","author":"Novello","year":"2023","journal-title":"Oncologist"},{"key":"2026070905463179900_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-023-00347-2","article-title":"Genomic landscape of 891 RET fusions detected across diverse solid tumor types","volume":"7","author":"Parimi","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2026070905463179900_bib44","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1007\/s00467-021-05061-4","article-title":"Congenital anomalies of the kidney and urinary tract in a cohort of 280 consecutive patients with Hirschsprung disease","volume":"36","author":"Pini Prato","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2026070905463179900_bib45","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1158\/1078-0432.CCR-18-4049","article-title":"Analysis of cell-free DNA from 32,989 advanced cancers reveals novel Co-occurring activating Ret alterations and oncogenic signaling pathway aberrations","volume":"25","author":"Rich","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026070905463179900_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2026070905463179900_bib47","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s00268-008-9734-2","article-title":"Pheochromocytoma in MEN 2A syndrome. Study of 54 patients","volume":"32","author":"Rodriguez","year":"2008","journal-title":"World J Surg"},{"key":"2026070905463179900_bib49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fendo.2012.00054","article-title":"RET\/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma","volume":"3","author":"Romei","year":"2012","journal-title":"Front Endocrinol"},{"key":"2026070905463179900_bib48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.2010.03900.x","article-title":"RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)","volume":"74","author":"Romei","year":"2011","journal-title":"Clin Endocrinol"},{"key":"2026070905463179900_bib50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hed.25463","article-title":"Different outcomes in sporadic versus familial medullary thyroid cancer","volume":"41","author":"Saltiki","year":"2019","journal-title":"Head Neck"},{"key":"2026070905463179900_bib51","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026070905463179900_bib52","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0172","article-title":"Real-world clinical profile, RET mutation testing, treatments, and PROs for MTC in Europe","volume":"13","author":"Segall","year":"2024","journal-title":"Eur Thyroid J"},{"key":"2026070905463179900_bib53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2021.09.012","article-title":"Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma","volume":"158","author":"Shankar","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026070905463179900_bib54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41576-023-00621-w","article-title":"Genomic newborn screening for rare diseases","volume":"24","author":"Stark","year":"2023","journal-title":"Nat Rev Genet"},{"key":"2026070905463179900_bib55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"2026070905463179900_bib56","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"2026070905463179900_bib57","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/jcp-2023-208890","article-title":"Landscape of cancer biomarker testing in England following genomic services reconfiguration: insights from a nationwide pathologist survey","volume":"77","author":"Taniere","year":"2024","journal-title":"J Clin Pathol"},{"key":"2026070905463179900_bib58","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1365-2265.2003.01782.x","article-title":"Frequent association between MEN 2A and cutaneous lichen amyloidosis","volume":"59","author":"Verga","year":"2003","journal-title":"Clin Endocrinol"},{"key":"2026070905463179900_bib59","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrendo.2011.139","article-title":"Management of medullary thyroid carcinoma and MEN2 syndromes in childhood","volume":"7","author":"Waguespack","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"2026070905463179900_bib60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"2026070905463179900_bib61","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1530\/EJE-08-0854","article-title":"Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B","volume":"160","author":"Zenaty","year":"2009","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/5\/ERC-24-0230.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/5\/ERC-24-0230.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0230\/145394\/erc-24-0230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0230\/145394\/erc-24-0230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:46:46Z","timestamp":1783590406000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/5\/e240230\/25990\/Genomic-testing-for-RET-in-the-clinic-UK-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0230","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"article-number":"e240230"}}